ZEPZELCA^®

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

MIMS Revision Date: 01 October 2025

1 Name of Medicine

Zepzelca 4 mg powder for solution for infusion.

2 Qualitative and Quantitative Composition

For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

4 mg of lurbinectedin as lyophilised powder in a single-dose vial for reconstitution.

4 Clinical Particulars

4.1 Therapeutic Indications

Zepzelca is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed on or after prior platinum-containing therapy. This indication was approved via the provisional approval pathway, based on objective response rate and duration of response in a single arm trial. Continued approval for this indication depends on verification and description of clinical benefit in a confirmatory trial.

4.2 Dose and Method of Administration

Zepzelca must be administered under the supervision of a physician experienced in the use of chemotherapy. Its use should be confined to qualified oncologists or other health professionals specialised in the administration of cytotoxic agents.
Recommended dose and schedule. The recommended dose is 3.2 mg/m² by intravenous infusion over 60 minutes, repeated once every 21 days until disease progression or unacceptable toxicity.
Only administer Zepzelca to patients with an absolute neutrophil count above 1.5 x 10⁹/L, and a platelet count above 100 x 10⁹/L.
Dose modifications for adverse reactions. The recommended dose reduction levels for adverse reactions are listed in Table 1. Dosage modifications for Zepzelca for adverse reactions are presented in Table 2. Permanently discontinue Zepzelca in patients who are unable to tolerate 2.0 mg/m² or require a dose delay greater than two weeks.

Discontinue Zepzelca if patients are unable to tolerate 2.0 mg/m² every 21 days.
Premedication. Pre-infusion, consider prophylactic administration of the following antiemetic medications:
Corticosteroids (intravenous dexamethasone 8 mg or equivalent);
Serotonin antagonists (intravenous ondansetron 8 mg or equivalent).
Preparation. Zepzelca is a cytotoxic drug. Follow applicable special handling and disposal procedures.
The Zepzelca vial is for single use (in one patient on one occasion) only. Discard any residue.
Prepare the solution for infusion using aseptic technique as follows:
Inject 8 mL of Sterile Water for Injection USP into the vial, yielding a reconstituted solution containing 0.5 mg/mL lurbinectedin.Shake the vial until dissolution is complete.
Visually inspect the reconstituted solution for particulate matter and discoloration. It should be clear, colourless or slightly yellowish, and free of visible particles.
Calculate the required volume of reconstituted solution as follows (see Equation 1):
For administration through a central venous line, withdraw the required volume of reconstituted solution from the vial and add to an infusion container containing at least 100 mL of diluent (0.9% Sodium Chloride Injection USP or 5% Glucose Injection).
For administration through a peripheral venous line, withdraw the required volume of reconstituted solution from the vial and add to an infusion container containing at least 250 mL of diluent (0.9% Sodium Chloride Injection USP or 5% Glucose Injection).
Use as soon as practicable after reconstitution and dilution. If necessary, the solution can be stored prior to administration, either at room temperature/in ambient light or, ideally, under refrigerated (2° to 8°C) conditions, for a maximum of 24 hours following reconstitution (including infusion time).
Administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter is observed, do not administer.
Zepzelca can be administered with or without an in-line filter. If infusion lines containing in-line filters are utilized for administration of Zepzelca, polyethersulfone (PES) in-line filters with pore sizes of 0.22 micron are recommended.
Do not use in-line nylon membrane filters when the reconstituted Zepzelca solution is diluted using 0.9% Sodium Chloride Injection, USP. Adsorption of Zepzelca to the Nylon membrane filters has been observed when 0.9% Sodium Chloride Injection, USP is used as the diluent.
Compatibility with other intravenous administration materials and the diluted Zepzelca solution has been demonstrated in the following materials:
Polyolefin containers (polyethylene, polypropylene and mixtures).
Polyvinyl Chloride (PVC) (non-DEHP-containing), polyurethane and polyolefin infusion sets (polyethylene, polypropylene and polybutadiene).
Implantable venous access systems with titanium and plastic resin ports and with polyurethane or silicone intravenous catheters.
Do not co-administer Zepzelca and other intravenous drugs concurrently within the same intravenous line.
Dose modification for hepatic impairment. Dose adjustment is not required for patients with mild hepatic impairment (total bilirubin ≤ 1.5 x ULN and AST ≤ 3 x ULN). The effect of moderate or severe hepatic impairment (total bilirubin > 1.5 x ULN) on the pharmacokinetics of lurbinectedin is unknown [see Section 5.2 Pharmacokinetic Properties].
Dose modification for renal impairment. Dose adjustment is not required in patients with mild to moderate (CL_CR 30-89 mL/min) renal impairment. The effect of severe renal impairment (CL_CR < 30 mL/min) or end-stage renal disease on the pharmacokinetics of lurbinectedin is unknown [see Section 5.2 Pharmacokinetic Properties]; therefore, it should not be administered to these patients.

4.3 Contraindications

Zepzelca is contraindicated in patients with history of significant drug allergy to the active substance or any of the excipients.

4.4 Special Warnings and Precautions for Use

Myelosuppression. Zepzelca can cause myelosuppression.
In clinical studies of 554 patients with advanced solid tumours receiving Zepzelca [see Section 4.8 Adverse Effects (Undesirable Effects)], Grade 3 or 4 neutropenia occurred in 41% of patients, with a median time to onset of 15 days and a median duration of 7 days. Febrile neutropenia occurred in 7% of patients. Sepsis occurred in 2% of patients and was fatal in 1% (all cases occurred in patients with solid tumours other than SCLC). Grade 3 or 4 thrombocytopenia occurred in 10%, with a median time to onset of 10 days and a median duration of 7 days. Grade 3 or 4 anaemia occurred in 17% of patients.
Administer Zepzelca only to patients with baseline neutrophil count of at least 1.5 x 10⁹/L and platelet count of at least 100 x 10⁹/L.
Monitor blood counts including neutrophil count and platelet count prior to each administration. For neutrophil count less than 0.5 x 10⁹/L or any value less than lower limit of normal, the use of G-CSF is recommended. Withhold, reduce the dose, or permanently discontinue Zepzelca based on severity [see Section 4.2 Dose and Method of Administration].
Hepatotoxicity. Zepzelca can cause hepatotoxicity.
In clinical studies of 554 patients with advanced solid tumours receiving Zepzelca [see Section 4.8 Adverse Effects (Undesirable Effects)], Grade 3 elevations of ALT and AST were observed in 6% and 3% of patients, respectively, and Grade 4 elevations of ALT and AST were observed in 0.4% and 0.5% of patients, respectively. The median time to onset of Grade ≥ 3 elevation in transaminases was 8 days (range: 3 to 49), with a median duration of 7 days.
Monitor liver function tests prior to initiating Zepzelca and periodically during treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue Zepzelca based on severity [see Section 4.2 Dose and Method of Administration].
Extravasation resulting in tissue necrosis. Extravasation of Zepzelca resulting in skin and soft tissue injury, including necrosis requiring debridement, may occur. Consider use of a central venous catheter to reduce the risk of extravasation, particularly in patients with limited venous access. Monitor patients for signs and symptoms of extravasation during the Zepzelca infusion. If extravasation occurs, immediately discontinue the infusion, remove the infusion catheter, and monitor for signs and symptoms of tissue necrosis. The time to onset of necrosis after extravasation may vary.
Administer supportive care and consult with an appropriate medical specialist as needed for signs and symptoms of extravasation. Administer subsequent infusions at a site that was not affected by extravasation.
Rhabdomyolysis. Rhabdomyolysis has been reported in patients treated with Zepzelca. Monitor creatine phosphokinase (CPK) prior to initiating Zepzelca and periodically during treatment as clinically indicated. Withhold or reduce the dose based on severity [see Section 4.2 Dose and Method of Administration].
If rhabdomyolysis occurs, supportive measures such as parenteral hydration, urine alkalinization and dialysis should be promptly established, as indicated. Caution should be taken if medicinal products with known association with rhabdomyolysis (e.g. statins), are administered concomitantly with lurbinectedin, since the risk of rhabdomyolysis may be increased.
Use in hepatic impairment. Zepzelca has not been studied in patients with AST > 3 x ULN, or in patients with moderate or severe hepatic impairment (bilirubin > 1.5 x ULN).
Use in renal impairment. Zepzelca has not been studied in patients with severe renal impairment (CL_CR < 30 mL/min) or end-stage renal disease.
Embryo-fetal toxicity. Based on animal data and its mechanism of action, Zepzelca can cause fetal harm when administered during pregnancy [see Section 4.6 Fertility, Pregnancy and Lactation].
Test to verify the pregnancy status of females of reproductive potential prior to initiating Zepzelca. Advise patients who are pregnant of the potential risk to the fetus. Advise female patients of reproductive potential to use highly effective contraception during treatment with Zepzelca and for 7 months after the last dose. Advise male patients with female partners of reproductive potential to use highly effective contraception during treatment with Zepzelca and for 4 months after the last dose.
Use in the elderly. Of the 105 patients with SCLC who received Zepzelca in clinical studies, 35% were ≥ 65 years of age, and 9% were ≥ 75 years of age. No overall difference in effectiveness was observed between patients who were ≥ 65 years of age compared to those who were < 65 years of age.
There was a higher incidence of serious adverse reactions in patients who were ≥ 65 years of age compared to those who were < 65 years of age (49% vs. 26%, respectively). The serious adverse reactions most frequently reported in patients ≥ 65 years of age were related to myelosuppression and consisted of febrile neutropenia (11%), neutropenia (11%), thrombocytopenia (8%), and anaemia (8%) [see Section 4.8 Adverse Effects (Undesirable Effects)].
Paediatric use. The safety and effectiveness of Zepzelca in paediatric patients have not been established.
Effects on laboratory tests. See Section 4.8 Adverse Effects (Undesirable Effects).

4.5 Interactions with Other Medicines and Other Forms of Interactions

Strong and moderate CYP3A inhibitors. Coadministration with a strong or a moderate CYP3A inhibitor is expected to increase lurbinectedin systemic exposure [see Section 5.2 Pharmacokinetic Properties] and may increase the incidence and severity of adverse reactions to Zepzelca.
Avoid coadministration of Zepzelca with strong CYP3A inhibitors (e.g. itraconazole, ketoconazole, posaconazole, voriconazole, or grapefruit) or moderate CYP3A inhibitors (e.g. aprepitant, ciprofloxacin, diltiazem, erythromycin, fluconazole, fluvoxamine, imatinib, or verapamil). For moderate CYP3A4 inhibitors, if coadministration with Zepzelca cannot be avoided, consider dose reduction of Zepzelca, based on individual tolerability as clinically indicated [see Section 4.2 Dose and Method of Administration].
Strong and moderate CYP3A inducers. Coadministration with a strong CYP3A inducer is expected to decrease lurbinectedin systemic exposure [see Section 5.2 Pharmacokinetic Properties] and may reduce Zepzelca efficacy. Avoid coadministration of Zepzelca with strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampicin, or St. John's wort) or moderate CYP3A inducers (e.g. bosentan, phenobarbital, or primidone).

4.6 Fertility, Pregnancy and Lactation

Effects on fertility. Zepzelca can cause embryolethality at doses lower than the human dose of 3.2 mg/m² [see Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy].
No dedicated fertility studies were conducted in animal species. Testicular atrophy and hypospermia were observed in rats and dogs at doses below the recommended clinical dose.
Pregnancy testing. Verify the pregnancy status of females of reproductive potential prior to initiating Zepzelca.
Contraception. Females. Advise female patients of reproductive potential to use highly effective contraception during and for 7 months after the use of Zepzelca.
Males. Advise males with a female sexual partner of reproductive potential to use highly effective contraception during and for 4 months after the use of Zepzelca.
Use in pregnancy. (Category D)
Based on animal data and its mechanism of action [see Section 5.1 Pharmacodynamic Properties], lurbinectedin can cause fetal harm when administered during pregnancy. There are no available clinical data to inform the risk of Zepzelca use during human pregnancy. Intravenous administration of a single lurbinectedin dose (approximately 0.2 times the 3.2 mg/m² clinical dose) to pregnant rats during the period of organogenesis caused 100% embryolethality.
Advise patients who are pregnant and females of reproductive potential of the potential risk to a fetus.
Use in lactation. There are no data on the presence of lurbinectedin in human milk, its effects on a breastfed child, or its effects on milk production. Because of the potential for serious adverse reactions from Zepzelca in breastfed children, advise patients not to breastfeed during treatment with Zepzelca and for 2 weeks after the final dose.

4.7 Effects on Ability to Drive and Use Machines

No studies on the effects of the ability to drive and to use machines have been performed. However, some events of fatigue, dizziness, vertigo and nausea have been reported in patients receiving lurbinectedin. Patients who experience such events during therapy should not drive or operate machinery.

4.8 Adverse Effects (Undesirable Effects)

The following clinically significant adverse reactions are described in detail in other sections of the prescribing information:
Myelosuppression [see Section 4.4 Special Warnings and Precautions for Use];
Hepatotoxicity [see Section 4.4 Special Warnings and Precautions for Use];
Extravasation resulting in tissue necrosis [see Section 4.4 Special Warnings and Precautions for Use];
Rhabdomyolysis [see Section 4.4 Special Warnings and Precautions for Use].
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in Section 4.4 Special Warnings and Precautions for Use reflects exposure to Zepzelca as a single agent at a dose of 3.2 mg/m² intravenously every 21 days in 554 patients with advanced solid tumours. Among 554 patients who received Zepzelca, including 105 patients with small cell lung cancer (SCLC) in PM1183-B-005-14 (Study B-005), 24% were exposed for 6 months or longer and 5% were exposed for greater than one year.
Small cell lung cancer (SCLC). The safety of Zepzelca was evaluated in a cohort of 105 patients with previously treated SCLC in Study B-005 [see Section 5.1 Pharmacodynamic Properties, Clinical trials]. Patients received Zepzelca 3.2 mg/m² intravenously every 21 days. All patients in this study received a pre-specified anti-emetic regimen consisting of a corticosteroid and serotonin antagonist. Patients could receive G-CSF for secondary prophylaxis (i.e. after patients had a first adverse event of leukopenia), but not primary prophylaxis (i.e. prior to any occurrence of leukopenia). Among patients who received Zepzelca, 29% were exposed for 6 months or longer and 6% were exposed for greater than one year.
Serious adverse reactions occurred in 34% of patients who received Zepzelca. Serious adverse reactions in ≥ 3% of patients included pneumonia, febrile neutropenia, neutropenia, respiratory tract infection, anaemia, dyspnoea, and thrombocytopenia.
Permanent discontinuation due to an adverse reaction occurred in two patients (1.9%) who received Zepzelca. Adverse reactions resulting in permanent discontinuation in ≥ 1% of patients who received Zepzelca, which included peripheral neuropathy and myelosuppression.
Dosage interruptions due to an adverse reaction occurred in 30.5% of patients who received Zepzelca. Adverse reactions requiring dosage interruption in ≥ 3% of patients who received Zepzelca included neutropenia, and hypoalbuminaemia.
Dose reductions due to an adverse reaction occurred in 25% of patients who received Zepzelca. Adverse reactions requiring dosage reductions in ≥ 3% of patients who received Zepzelca included neutropenia, febrile neutropenia and fatigue.
The most common adverse reactions, including laboratory abnormalities, (≥ 20%) were leukopenia, lymphopenia, fatigue, anaemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnoea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhoea.
The most common adverse reactions, and selected laboratory abnormalities that occurred in the SCLC cohort of Study B-005 are summarised in Table 3 and Table 4, respectively.

Clinically relevant adverse reactions in < 10% of patients who received Zepzelca included dysgeusia, febrile neutropenia and pneumonitis.
Post-marketing experience. The following adverse reactions have been identified during post-approval use of Zepzelca. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General disorders and administration site conditions. Extravasation (including tissue necrosis requiring debridement).
Musculoskeletal and connective tissue disorders. Rhabdomyolysis.
Metabolism and nutrition disorders. Tumour lysis syndrome.
Reporting suspected adverse effects. Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems and drugsafety-STA@stbiopharma.com.

4.9 Overdose

If an overdose is suspected, monitor the patient closely for myelosuppression and hepatic enzymes and institute supportive care measures as appropriate.
Haemodialysis is not expected to enhance the elimination of Zepzelca because lurbinectedin is highly bound to plasma proteins (99%), and renal excretion is negligible.
There is no known antidote for overdosage with Zepzelca.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action. Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.
Lurbinectedin inhibited human monocyte activity in vitro and reduced macrophage infiltration in implanted tumours in mice.
Pharmacodynamics. Lurbinectedin exposure-response relationships and the pharmacodynamic time-course for efficacy have not been fully characterised.
Increased incidence of Grade 4 neutropenia and Grade ≥ 3 thrombocytopenia were observed with increased lurbinectedin exposure.
Cardiac electrophysiology. The potential for QT prolongation with lurbinectedin was evaluated in a sub-study of 39 patients with advanced cancer who received lurbinectedin 3.2 mg/m² every 3 weeks in Study B-005. No large mean increase in QTcF (> 20 ms) was detected. The maximum mean QTcF change from baseline was 5.4 ms (upper bound of 90% CI: 9.6 ms).
Clinical trials. Study B-005. Study B-005 (PM1183-B-005-14) was an open-label, multicentre, single-arm study evaluating Zepzelca as a single agent in patients with advanced or metastatic solid tumours, including a cohort of patients with small cell lung cancer (SCLC) whose disease had progressed on or after platinum-based chemotherapy. Patients received 3.2 mg/m² Zepzelca, administered as a 60-minute IV infusion once every 21 days (one cycle). Patients received a median of 4 cycles of Zepzelca (range 1 to 24 cycles). The trial excluded patients with central nervous system (CNS) involvement, grade ≥ 3 dyspnoea, daily intermittent oxygen requirement, hepatitis or cirrhosis, and immunocompromised patients. Tumour assessments were conducted every 6 weeks for the first 18 weeks and every 9 weeks thereafter. The primary efficacy outcome measure was confirmed, investigator-assessed, overall response rate (ORR), using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additional efficacy outcome measures included investigator-assessed duration of response (DOR), as well as ORR and DOR assessed by an Independent Review Committee (IRC).
A total of 105 patients with SCLC who progressed on or after platinum-based chemotherapy were enrolled. The median age was 60 years (range, 40-83 years) and 35% were at least 65 years old. The majority of patients were male (60%) and white (75%); ethnicity was not reported for 23%. Baseline ECOG performance status was 0 or 1 for 92% of patients, and 92% were current/former smokers. All patients had received at least one line of platinum-based chemotherapy for advanced disease (range 1-2 lines), and prior radiotherapy had been administered to 71% of patients. Eight patients (8%) had prior immunotherapy in addition to platinum-based chemotherapy. Sixty patients (57%) had platinum-sensitive SCLC, defined as recurrence or progression ≥ 90 days after the last dose of platinum-containing therapy (chemotherapy free interval [CTFI] ≥ 90 days). The remaining 45 patients had platinum-resistant SCLC, defined as recurrence or progression < 90 days after the last dose of platinum-containing therapy (CTFI < 90 days).
Table 5 summarises investigator-assessed and IRC-assessed key efficacy measures in all patients and in platinum-resistant and platinum-sensitive subgroups.

5.2 Pharmacokinetic Properties

After a 3.2 mg/m² lurbinectedin dose administered as a 1-hour IV infusion, geometric means (CV%) of total plasma C_max and AUC_0-inf were 107 microgram/L (79%) and 551 microgram.h/L (94%), respectively. No accumulation of lurbinectedin in plasma is observed upon repeated administrations every 3 weeks.
Distribution. The volume of distribution (CV%) of lurbinectedin at steady state is 504 L (39%). Plasma protein binding is approximately 99%, to both albumin and α-1-acid glycoprotein.
Metabolism. Lurbinectedin is metabolised by CYP3A4 in vitro.
Excretion. The terminal half-life of lurbinectedin is 51 hours. Total plasma clearance (CV%) of lurbinectedin is 11 L/h (50%).
After administration of a single dose of radiolabeled lurbinectedin, 89% of the radioactivity was recovered in faeces (< 0.2% unchanged) and 6% was recovered in urine (1% unchanged).
Drug interaction studies. Lurbinectedin is metabolised by CYP3A4 in vitro, and interactions with strong and moderate CYP3A inhibitors and inducers are anticipated. Dedicated clinical drug-drug interaction studies with CYP3A modulators have not been completed.
In a Phase 1 study with lurbinectedin, patients who received aprepitant (a weak-moderate CYP3A4 inhibitor used as an antiemetic) showed a 33% reduction of lurbinectedin plasma clearance when compared with patients who did not receive it.
In vitro data. Cytochrome P450 (CYP) enzymes. Lurbinectedin is metabolised by CYP3A4.
At clinically relevant concentrations, lurbinectedin is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4.
Lurbinectedin is not an inducer of CYP1A2 or CYP3A4.
Transporter systems. Lurbinectedin is a substrate of MDR1 (P-gp), but is not a substrate of OATP1B1, OATP1B3, OCT1, or MATE1.
Lurbinectedin inhibits MDR1 (P-gp), OATP1B1, OATP1B3, and OCT1 but not BCRP, BSEP, MATE1, OAT1, OAT3, or OCT2.
Pharmacokinetics in specific populations. No clinically significant differences in the pharmacokinetics of lurbinectedin were identified based on age (range: 18-85 years), sex, body weight (range: 39-154 kg), mild to moderate renal impairment (CL_CR 30 to 89 mL/min) or mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin between 1.0-1.5 x ULN and any AST). The effects of severe renal impairment (CLcr < 30 mL/min) and moderate or severe hepatic impairment (total bilirubin > 1.5 x ULN and any AST) on the pharmacokinetics of lurbinectedin have not been studied.

5.3 Preclinical Safety Data

Genotoxicity. Lurbinectedin is genotoxic to mammalian cells in the presence and absence of metabolic activation, and was positive in the mouse lymphoma cell assay. Lurbinectedin was not mutagenic in vitro in a bacterial reverse mutation (Ames) assay.
Carcinogenicity. Carcinogenicity testing of lurbinectedin has not been performed.

6 Pharmaceutical Particulars

6.1 List of Excipients

(S)-lactic acid; sucrose; sodium hydroxide.

6.2 Incompatibilities

Zepzelca must not be mixed or diluted with other medicinal products except those mentioned in Section 4.2.

6.3 Shelf Life

Unopened vials. 60 months [see Section 6.4 Special Precautions for Storage].
After reconstitution or dilution. 24 hours, including infusion time. Use immediately if possible [see Section 6.4 Special Precautions for Storage].
In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Unopened vials. Refrigerate (2° to 8°C). Refrigerate. Do not freeze.
After reconstitution or dilution. Stable at room temperature with exposure to ambient light for up to 24 hours. However, microbiological hazard is minimized by immediate use, or refrigeration (2° to 8°C) if storage is necessary. Do not store for longer than 24 hours, including infusion time. Do not freeze.

6.5 Nature and Contents of Container

Zepzelca (lurbinectedin) powder for solution for infusion is supplied as a sterile, preservative-free, lyophilised powder in a 30 mL clear glass vial. Each carton contains one single-dose vial.

6.6 Special Precautions for Disposal

Zepzelca is a cytotoxic drug. Follow applicable special handling and disposal procedures.
In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Zepzelca is a synthetic molecule, which binds to the minor groove of DNA and is a selective inhibitor of oncogenic transcription. The chemical name of Zepzelca (lurbinectedin) is (1'R,6R,6aR,7R,13S,14S,16R)-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-19-oxo- 2',3',4',6,7,9',12,13,14,16-decahydro-6aH-spiro[7,13-azano-6,16-(epithiopropanooxymethano) [1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'-pyrido[3,4-b]indol]-5-yl acetate.
Molecular formula: C₄₁H₄₄N₄O₁₀S.
Molecular weight: 784.87 g/mol.
Chemical structure.

CAS number. 497871-47-3.

7 Medicine Schedule (Poisons Standard)

Prescription Only Medicine (S4).

Date of First Approval

10 September 2021

Date of Revision

05 September 2025

Summary Table of Changes